2014
AACR Celebrates 50 Years of Tobacco Research and Policy
Herbst RS, Hobin JA, Gritz ER, Tobacco and Cancer W. AACR Celebrates 50 Years of Tobacco Research and Policy. Clinical Cancer Research 2014, 20: 1709-1718. PMID: 24691637, DOI: 10.1158/1078-0432.ccr-14-0427.Peer-Reviewed Original Research
2013
Reducing Tobacco‐Related Cancer Incidence and Mortality: Summary of an Institute of Medicine Workshop
Balogh EP, Dresler C, Fleury ME, Gritz ER, Kean TJ, Myers ML, Nass SJ, Nevidjon B, Toll BA, Warren GW, Herbst RS. Reducing Tobacco‐Related Cancer Incidence and Mortality: Summary of an Institute of Medicine Workshop. The Oncologist 2013, 19: 21-31. PMID: 24304712, PMCID: PMC3903060, DOI: 10.1634/theoncologist.2013-0230.Peer-Reviewed Original ResearchPractice Patterns and Perceptions of Thoracic Oncology Providers on Tobacco Use and Cessation in Cancer Patients
Warren GW, Marshall JR, Cummings KM, Toll B, Gritz ER, Hutson A, Dibaj S, Herbst R, Dresler C, Committee I. Practice Patterns and Perceptions of Thoracic Oncology Providers on Tobacco Use and Cessation in Cancer Patients. Journal Of Thoracic Oncology 2013, 8: 543-548. PMID: 23529191, PMCID: PMC3628367, DOI: 10.1097/jto.0b013e318288dc96.Peer-Reviewed Original ResearchConceptsCancer patientsTobacco useOncology providersPractice patternsClinical careInitial patient visitTobacco cessation activitiesLung cancer patientsTobacco cessation methodsCessation activitiesMedication optionsCessation assistanceCessation interventionsPoor outcomeSmoking cessationTobacco cessationCessation effortsCancer careLung cancerCessation methodsAffect OutcomesPatient visitsPhysician respondentsTobacco assessmentClinician educationAssessing Tobacco Use by Cancer Patients and Facilitating Cessation: An American Association for Cancer Research Policy Statement
Toll BA, Brandon TH, Gritz ER, Warren GW, Herbst RS, Tobacco and Cancer W. Assessing Tobacco Use by Cancer Patients and Facilitating Cessation: An American Association for Cancer Research Policy Statement. Clinical Cancer Research 2013, 19: 1941-1948. PMID: 23570694, PMCID: PMC5992896, DOI: 10.1158/1078-0432.ccr-13-0666.Peer-Reviewed Original ResearchConceptsTobacco useTobacco cessationCessation interventionsEvidence-based cessation interventionsTreatment-related toxicitySecond primary tumorsTobacco cessation interventionsQuality cancer careQuality of lifeAmerican AssociationCessation assistancePoor outcomeCancer careCancer patientsPrimary tumorOncology settingCancer recurrencePatientsTreatment efficacyTreatment settingsEvidence-based proceduresCancer leadCancerCancer progressionClinical infrastructureCXCR2 Expression in Tumor Cells Is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung Adenocarcinoma
Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Soto L, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 Expression in Tumor Cells Is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung Adenocarcinoma. Cancer Research 2013, 73: 571-582. PMID: 23204236, PMCID: PMC3548940, DOI: 10.1158/0008-5472.can-12-0263.Peer-Reviewed Original ResearchConceptsGene expression profilesNon-small cell lung cancerKnockdown clonesNSCLC cell linesHuman NSCLC cell linesExpression profilesCell linesStable knockdown clonesLung adenocarcinomaLung adenocarcinoma cell linesTumor cellsRAS pathway activationCXCR2 expressionPoor prognosisLung cancer cellsOrthotopic syngeneic mouse modelAdenocarcinoma cell linePromotes InvasionExpression of CXCL5Role of CXCR2Poor prognostic factorCell lung cancerPromoter methylationSyngeneic mouse modelProtein expression
2012
Tobacco Assessment in Actively Accruing National Cancer Institute Cooperative Group Program Clinical Trials
Peters EN, Torres E, Toll BA, Cummings KM, Gritz ER, Hyland A, Herbst RS, Marshall JR, Warren GW. Tobacco Assessment in Actively Accruing National Cancer Institute Cooperative Group Program Clinical Trials. Journal Of Clinical Oncology 2012, 30: 2869-2875. PMID: 22689794, PMCID: PMC3410402, DOI: 10.1200/jco.2011.40.8815.Peer-Reviewed Original ResearchConceptsCooperative group clinical trialsGroup clinical trialTobacco use assessmentClinical trialsTobacco useCancer treatment outcomesTreatment outcomesTobacco assessmentEvidence-based cessation supportPhase III trialsSecondhand smoke exposureClinical oncology practiceCooperative Group ProgramCancer clinical trialsCurrent cigarette useIII trialsSmoke exposureCessation supportNeck trialsOncology practiceNicotine dependenceRoutine assessmentCigarette useTrialsGroup program
2010
Tobacco and Cancer: An American Association for Cancer Research Policy Statement
Viswanath K, Herbst RS, Land SR, Leischow SJ, Shields PG, Tobacco and Cancer W. Tobacco and Cancer: An American Association for Cancer Research Policy Statement. Cancer Research 2010, 70: 3419-3430. PMID: 20388799, DOI: 10.1158/0008-5472.can-10-1087.Peer-Reviewed Original ResearchConceptsTobacco-related cancersTobacco useEvidence-based strategiesTobacco productsTobacco controlNew evidence-based strategiesEffective tobacco control strategiesTobacco-related deathsOncology clinical trialsEvidence-based behavioralFormer tobacco usersTobacco-related diseasesTobacco control programsEvidence-based treatmentsWorld Health Organization Framework ConventionTobacco control strategiesNew tobacco productsPublic healthAmerican AssociationAddictive componentTobacco cessationPharmacological treatmentClinical trialsTobacco usersEffective treatment
2008
Lung Cancer
Herbst RS, Heymach JV, Lippman SM. Lung Cancer. New England Journal Of Medicine 2008, 359: 1367-1380. PMID: 18815398, PMCID: PMC10662965, DOI: 10.1056/nejmra0802714.Peer-Reviewed Original Research
2001
Lung cancer in patients under age 40
Skarin A, Herbst R, Leong T, Bailey A, Sugarbaker D. Lung cancer in patients under age 40. Lung Cancer 2001, 32: 255-264. PMID: 11390007, DOI: 10.1016/s0169-5002(00)00233-6.Peer-Reviewed Original ResearchConceptsStage IV diseaseSmall cell carcinomaSquamous cell carcinomaCell carcinomaPerformance statusStage IIIBStage IIIAOlder patientsLung cancerYear survivalAge 40Stage I/IIDana-Farber Cancer InstituteGreater body weight lossWeight lossECOG performance statusPercent of patientsPoor performance statusDuration of symptomsSite of metastasisOverall patient survivalStage of diseaseBody weight lossAbsence of symptomsPercentage of women